2023-508690-92-00招募中4 期
A multicenter rollover extension program (REP) to evaluate the long-term safety and tolerability of open label iptacopan in adult participants with primary IgA nephropathy who have completed a Novartis-sponsored iptacopan parent study in IgAN
干预措施
试验速览
- 阶段
- 4 期
- 状态
- 招募中
- 入组人数
- 100
- 试验地点
- 38
- 主要终点
- Safety and tolerability endpoints (including but not limited to AEs/SAEs, safety laboratory parameters, vital signs).
研究概览
简要总结
The primary objective is to evaluate the long-term safety and tolerability of iptacopan in eligible participants.
入排标准
- 年龄范围
- 18 years 至 65+ years（18-64 Years, 65+ Years）
- 接受健康志愿者
- 是
入选标准
- •Signed informed consent must be obtained prior to participation in the REP; participants should be able to communicate well with the Investigator, understand and comply with the requirements of the study.
- •For CLNP023X2203, participants must have completed Part 1 or Part 2 of the trial. For other parent trials participants must have completed the entire parent trial duration defined by the respective protocol.
- •eGFR* ≥ 20 mL/min/1.73m
- •eGFR calculated using the CKD-EPI formula (or modified MDRD formula according to specific ethnic groups and local practice guidelines).
- •Per Investigator’s clinical judgment, the participant may benefit from receiving the open-label treatment of iptacopan 200 mg b.i.d.
- •Prior vaccination against Neisseria meningitidis, Streptococcus pneumoniae and Haemophilus influenzae infections should be up to date (i.e. any boosters required administered according to local regulations).
- •All participants must be on supportive care regimen of stable dose of ACEi or ARB* as per KDIGO guidelines (KDIGO 2021). * Participants with allergies or intolerance to ACEi and ARB are eligible for the study but the Investigator should clearly document the reasons for not being on maximal ACEi/ARB dose in the source documents.
排除标准
- •Participants who are screen or baseline failed in any of the iptacopan parent studies in IgAN or who prematurely withdrew from iptacopan parent studies in IgAN for any reason.
- •Any medical condition deemed likely to interfere with the participant’s participation in the study.
- •Active systemic bacterial, viral (including COVID-19) or fungal infection within 14 days prior to study treatment administration.
- •Presence of fever ≥ 38°C (100.4°F) within 7 days prior to study treatment administration.
- •History of Human Immunodeficiency Virus (HIV) infection (known history of HIV or test positive for HIV antibody at Screening).
- •Liver disease or liver injury as indicated by abnormal liver function tests (LFT) at screening as defined below. ALT (SGPT), AST (SGOT), GGT, alkaline phosphatase and serum bilirubin will be tested. • Any single parameter of ALT, AST, GGT, alkaline phosphatase must not exceed 3 × upper limit of normal (ULN) • Serum bilirubin must not exceed 2 × ULN Participants from CLNP023X2203 study or any other parent study participants if required by local regulations will be additionally tested for HBsAg and HCV-RNA and are not eligible if the results are positive.
- •History of hypersensitivity to any of the study treatments or its excipients or to drugs of similar chemical classes or any participant who discontinued study treatment in the parent study due to a suspected treatment-related AE.
- •History of malignancy of any organ system (other than localized basal cell carcinoma of the skin or in situ cervical cancer treated with curative intent), treated or untreated, within the past 5 years, regardless of whether there is evidence of local recurrence or metastases.
- •Pregnant or breastfeeding females, where pregnancy is confirmed by a positive Human Chorionic Gonadotrophin (HCG) test.
- •Evidence of severe urinary obstruction or difficulty in voiding; any urinary tract disorder other than IgAN at screening and before dosing with iptacopan.
- •Current (within 4 weeks prior to study treatment administration in the REP) acute kidney injury (AKI) defined by AKIN criteria.
- •Presence of Rapidly Progressive Glomerulonephritis (RPGN) as defined by 50% decline in eGFR within the last 3 months.
- •Participants treated with immunosuppressive or other immunomodulatory agents such as but not limited to cyclophosphamide, rituximab, infliximab, eculizumab, canakinumab, mycophenolate mofetil (MMF) or mycophenolate sodium (MPS), cyclosporine, tacrolimus, sirolimus, everolimus and/or systemic corticosteroids exposure (>7.5 mg/d prednisone/prednisolone equivalent) within 90 days prior to first study drug administration. Rituximab requires 180 days wash out. Participants treated with endothelin (receptor) antagonists within 90 days prior to first study drug administration.
- •Use of other investigational drugs at the time of enrollment, or within 5 half-lives of enrollment or within 30 days whichever is longer
- •History of recurrent invasive infections caused by encapsulated organisms, such as Neisseria meningitidis, Streptococcus pneumoniae and Hemophilus influenzae.
- •All transplanted participants (any solid organ, or bone marrow transplantation).
- •Major concurrent comorbidities including but not limited to severe uncontrolled hypertension, other chronic kidney disease (with or without kidney failure), advanced cardiac disease (e.g., NYHA class IV), severe pulmonary disease (e.g., severe pulmonary hypertension (WHO class IV), or hepatic disease (e.g. active hepatitis) that in the opinion of the Investigator precludes participant's participation in the study.
研究组 & 干预措施
-, -
Auxiliary
Participants receiving -, -
干预措施: - (Drug)
-
Auxiliary
Participants receiving -
干预措施: - (Drug)
结局指标
主要结局
Safety and tolerability endpoints (including but not limited to AEs/SAEs, safety laboratory parameters, vital signs).
Safety and tolerability endpoints (including but not limited to AEs/SAEs, safety laboratory parameters, vital signs).
次要结局
- Annualized total eGFR slope.
- Change from baseline in eGFR.
- Log transformed ratio to baseline in UPCR, UACR.
研究者
Novartis Pharma Arzneimittel GmbH
Scientific
Novartis Pharma AG
研究点 (38)
Loading locations...
相似试验
招募中
3 期
Study to assess the pharmacokinetics, safety, and tolerability of iptacopan in pediatric PNH patients2024-515926-10-00Novartis Pharma AG5
招募中
3 期
Evaluate long-term safety, tolerability and efficacy of iptacopan in study participants with aHUS2022-502965-34-00Novartis Pharma AG6
招募中
2 期
A randomized, controlled study to evaluate LNP023 (iptacopan) in patients with active ANCA-associated vasculitis.2023-510525-15-00Novartis Pharma AG44
招募中
3 期
A Long term Safety and Efficacy Study of Danicopan as an Add-on Therapy to C5i in Patients with PNH.2023-504867-18-00Alexion Pharmaceuticals Inc., Alexion Pharmaceuticals Inc.25
招募中
3 期
Long Term Study of Ecopipam Tablets in Children, Adolescents and Adults with Tourette’s Disorder2023-503545-67-00Emalex Biosciences Inc.38